NASDAQ:TNGX Tango Therapeutics (TNGX) Stock Forecast, Price & News $2.99 +0.07 (+2.40%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$2.90▼$3.1550-Day Range$2.92▼$4.7052-Week Range$2.88▼$8.56Volume130,632 shsAverage Volume138,487 shsMarket Capitalization$264.35 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Tango Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside435.1% Upside$16.00 Price TargetShort InterestHealthy3.59% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.40) to ($1.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.22 out of 5 starsMedical Sector400th out of 1,012 stocksPharmaceutical Preparations Industry182nd out of 495 stocks 3.5 Analyst's Opinion Consensus RatingTango Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, Tango Therapeutics has a forecasted upside of 435.1% from its current price of $2.99.Amount of Analyst CoverageTango Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.59% of the float of Tango Therapeutics has been sold short.Short Interest Ratio / Days to CoverTango Therapeutics has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.Change versus previous monthShort interest in Tango Therapeutics has recently decreased by 18.02%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTango Therapeutics does not currently pay a dividend.Dividend GrowthTango Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TNGX. Previous Next 3.6 News and Social Media Coverage News SentimentTango Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Tango Therapeutics this week, compared to 1 article on an average week.Search Interest4 people have searched for TNGX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Tango Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tango Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Tango Therapeutics is held by insiders.Percentage Held by Institutions77.30% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tango Therapeutics are expected to grow in the coming year, from ($1.40) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tango Therapeutics is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tango Therapeutics is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTango Therapeutics has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Tango Therapeutics (NASDAQ:TNGX) StockTango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.Read More Receive TNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TNGX Stock News HeadlinesMay 14, 2023 | americanbankingnews.comSVB Leerink Analysts Raise Earnings Estimates for Tango Therapeutics, Inc. (NASDAQ:TNGX)May 12, 2023 | msn.comWedbush Reiterates Tango Therapeutics (TNGX) Outperform RecommendationMay 28, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 12, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for Tango Therapeutics, Inc. Issued By Wedbush (NASDAQ:TNGX)May 9, 2023 | finance.yahoo.comTango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue EstimatesMay 9, 2023 | msn.comTango Therapeutics: Q1 Earnings InsightsMay 9, 2023 | markets.businessinsider.comGoldman Sachs Sticks to Its Buy Rating for Tango Therapeutics (TNGX)May 9, 2023 | finanznachrichten.deTango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business HighlightsMay 28, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 9, 2023 | finance.yahoo.comTango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business HighlightsApril 18, 2023 | finance.yahoo.comTango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual MeetingApril 3, 2023 | tmcnet.comTango Therapeutics Announces FDA Clearance of Investigational NewApril 3, 2023 | finance.yahoo.comTango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant CancersApril 1, 2023 | americanbankingnews.comTango Therapeutics, Inc. to Post Q1 2023 Earnings of ($0.37) Per Share, SVB Leerink Forecasts (NASDAQ:TNGX)March 30, 2023 | americanbankingnews.comAnalysts Set Expectations for Tango Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:TNGX)March 30, 2023 | americanbankingnews.comWedbush Research Analysts Raise Earnings Estimates for Tango Therapeutics, Inc. (NASDAQ:TNGX)March 30, 2023 | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) Price Target Increased to $11.00 by Analysts at HC WainwrightMarch 29, 2023 | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPSMarch 29, 2023 | americanbankingnews.comBrokers Set Expectations for Tango Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TNGX)March 28, 2023 | msn.comTango Therapeutics GAAP EPS of -$0.33 beats by $0.03, revenue of $6.41M beats by $0.09MMarch 28, 2023 | msn.comLooking Into Tango Therapeutics's Return On Capital EmployedMarch 28, 2023 | markets.businessinsider.comTango Therapeutics (TNGX) Receives a Buy from H.C. WainwrightMarch 27, 2023 | finanznachrichten.deTango Therapeutics, Inc.: Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business HighlightsMarch 27, 2023 | finance.yahoo.comTango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue EstimatesMarch 27, 2023 | finance.yahoo.comTango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business HighlightsMarch 27, 2023 | finance.yahoo.comTango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business HighlightsMarch 17, 2023 | seekingalpha.comTNGX Tango Therapeutics, Inc.See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TNGX Company Calendar Last Earnings5/09/2023Today5/28/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TNGX CUSIPN/A CIK1819133 Webwww.tangotx.com Phone857-320-4900FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.00 High Stock Price Forecast$21.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+435.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,180,000.00 Net Margins-446.26% Pretax Margin-446.04% Return on Equity-42.34% Return on Assets-25.33% Debt Debt-to-Equity RatioN/A Current Ratio6.39 Quick Ratio6.39 Sales & Book Value Annual Sales$24.86 million Price / Sales10.63 Cash FlowN/A Price / Cash FlowN/A Book Value$2.57 per share Price / Book1.16Miscellaneous Outstanding Shares88,410,000Free Float85,136,000Market Cap$264.35 million OptionableNot Optionable Beta1.62 Key ExecutivesDr. Barbara L. Weber M.D. (Age 66)Pres, CEO & Director Comp: $796.2kMs. Daniella Beckman CPA (Age 43)Chief Financial Officer Comp: $545.82kDr. Alan Huang Ph.D. (Age 49)Chief Scientific Officer Comp: $566.54kDr. Alan Ashworth FRS (Age 61)Ph.D., Founder & Member of Scientific Advisory Board Dr. Levi Garraway M.D.Ph.D., FounderDr. William G. Kaelin Jr. (Age 64)M.D., Founder & Member of Scientific Advisory Board Dr. Timothy K. Lu M.D. (Age 41)Ph.D., Founder Dr. Antoni Ribas M.D. (Age 55)Ph.D., Founder & Member of Scientific Advisory Board Mr. Douglas J. Barry Esq. (Age 52)J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. Mr. John C. Ross M.S.VP of HRMore ExecutivesKey CompetitorsVera TherapeuticsNASDAQ:VERAPrecigenNASDAQ:PGENApollomicsNASDAQ:APLMKalVista PharmaceuticalsNASDAQ:KALVVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Bought 24,434 shares on 5/22/2023Ownership: 0.059%JPMorgan Chase & Co.Bought 10,980 shares on 5/18/2023Ownership: 0.069%New York State Common Retirement FundSold 12,378 shares on 5/18/2023Ownership: 0.024%State Street CorpSold 22,340 shares on 5/16/2023Ownership: 0.929%Jane Street Group LLCBought 14,624 shares on 5/16/2023Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions TNGX Stock - Frequently Asked Questions Should I buy or sell Tango Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TNGX shares. View TNGX analyst ratings or view top-rated stocks. What is Tango Therapeutics' stock price forecast for 2023? 1 brokers have issued 1 year price targets for Tango Therapeutics' shares. Their TNGX share price forecasts range from $11.00 to $21.00. On average, they anticipate the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 435.1% from the stock's current price. View analysts price targets for TNGX or view top-rated stocks among Wall Street analysts. How have TNGX shares performed in 2023? Tango Therapeutics' stock was trading at $7.25 at the beginning of 2023. Since then, TNGX stock has decreased by 58.8% and is now trading at $2.99. View the best growth stocks for 2023 here. Are investors shorting Tango Therapeutics? Tango Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 1,820,000 shares, a drop of 18.0% from the April 30th total of 2,220,000 shares. Based on an average daily trading volume, of 166,100 shares, the short-interest ratio is currently 11.0 days. Currently, 3.6% of the shares of the company are short sold. View Tango Therapeutics' Short Interest. When is Tango Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our TNGX earnings forecast. How were Tango Therapeutics' earnings last quarter? Tango Therapeutics, Inc. (NASDAQ:TNGX) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.04. The company had revenue of $5.77 million for the quarter, compared to analysts' expectations of $6.70 million. Tango Therapeutics had a negative trailing twelve-month return on equity of 42.34% and a negative net margin of 446.26%. What ETFs hold Tango Therapeutics' stock? ETFs with the largest weight of Tango Therapeutics (NASDAQ:TNGX) stock in their portfolio include Invesco DWA SmallCap Momentum ETF (DWAS), Invesco Nasdaq Biotechnology ETF (IBBQ). What is Tango Therapeutics' stock symbol? Tango Therapeutics trades on the NASDAQ under the ticker symbol "TNGX." Who are Tango Therapeutics' major shareholders? Tango Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (10.78%), BlackRock Inc. (4.00%), Geode Capital Management LLC (1.00%), State Street Corp (0.93%), Bank of New York Mellon Corp (0.16%) and Swiss National Bank (0.12%). View institutional ownership trends. How do I buy shares of Tango Therapeutics? Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Tango Therapeutics' stock price today? One share of TNGX stock can currently be purchased for approximately $2.99. How much money does Tango Therapeutics make? Tango Therapeutics (NASDAQ:TNGX) has a market capitalization of $264.35 million and generates $24.86 million in revenue each year. The company earns $-108,180,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. How can I contact Tango Therapeutics? Tango Therapeutics' mailing address is 12860 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.tangotx.com. The company can be reached via phone at 857-320-4900. This page (NASDAQ:TNGX) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.